Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidation nivolumab + ipilimumab after chemoradiotherapy in limited-stage small cell lung cancer
2013-002609-78Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in small cell lung cancer (SCLC) (2 arms), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Overall survival. Started Jan 2014; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2013-002609-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002609-78.